Despite recent strides in medical innovation – in oncology, COVID-19, neurodegenerative disorders and other disease states – we’re still behind in women’s health. In 2018, the FDA granted 59 new drug approvals, a record number; only three addressed women’s health concerns. Since then, products for women remain a fraction of total FDA approvals, comprising only four of 53 in 2020 and just five of 41 in 2021. However, there is new innovation for women in the pipeline, and more companies are paying attention to, and investing in, women’s health. There is now an opportunity to accelerate this momentum, creating and fueling an ecosystem of innovation fostered by collaboration, deal-making and fair valuations. This panel will cover the promising green shoots of opportunity in the global pipeline today, and how to speed these advancements and bring them to market in such a way that creates a sustainable business while eliminating gender disparities.